Related references
Note: Only part of the references are listed.The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity
RM Prins et al.
JOURNAL OF IMMUNOLOGY (2006)
Delivery of dendritic cells engineered to secrete IFN-α into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines:: Dependence on apoptotic pathways
N Kuwashima et al.
JOURNAL OF IMMUNOLOGY (2005)
Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod
G Rechtsteiner et al.
JOURNAL OF IMMUNOLOGY (2005)
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy - Case report
S De Vleeschouwer et al.
JOURNAL OF NEUROSURGERY (2004)
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma
Y Akasaki et al.
JOURNAL OF IMMUNOLOGY (2004)
Transcriptional expression of survivin and its splice variants in brain tumors in humans
Y Yamada et al.
JOURNAL OF NEUROSURGERY (2003)
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation
S Nair et al.
JOURNAL OF IMMUNOLOGY (2003)
Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality
CJ Wheeler et al.
JOURNAL OF IMMUNOLOGY (2003)
Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor
RE McLendon et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2000)
Share Paper
